anti-thymocyte globulin Clinical Research Trials | TrialX

Loading...

Please select a valid location from the dropdown

Filter By

Clear all Advanced

Advanced Filters

Gender
Phase
Study Type
Sponsors
Accepts healthy volunteers
Online Trials
Age Group

Any (1)

Phase 3 (1)

Interventional (1)

Indiana University (1)

No (1)

No (1)

Adult (18+) (1)

I am/have/had

I am/have/hadnephropathy

I am/have/hadchronic kidney disease

I am/have/hadrenal toxicity

I am/have/hadrenal failure

I am/have/hadcancer

I am/have/hadrenal injury

I am/have/hadhypertension

I am/have/hadhyperlipidemia

I am/have/hadacute renal failure

I am/have/hadorgan rejection

I am/have/hadhepatitis c

I am/have/hadnephrotoxicity

I am/have/hadtacrolimus

I am/have/hadrenal impairment

I am/have/hadproteinuria

I am/have/hadimmunosuppression

I am/have/haddiabetes

I am/have/hadhepatitis b

I am/have/hadliver transplant

I am/have/hadrenal function test

added new label for I am/have/had

more

I am looking for

I am looking formycophenolate

I am looking foreverolimus

I am looking formycophenolic acid

I am looking forhepatitis b

I am looking forantithymocyte globulin

I am looking forimmunosuppressive agents

I am looking forrabbit atg

I am looking formycophenolate mofetil

I am looking foranti-thymocyte globulin

I am looking fortacrolimus

added new label for I am looking for

more

Advanced Filters

Loading...

Found 1 clinical trials

We call this “infoimagery”. It is unique to every trial and is generated based on a trials specific data eg. therapeutic area, study type, phase etc. and the centerwatch system associates the information to a matching set of related symbols and icons.

What's this?

Phase 3
For Seniors
For adults
Recruiting in 100s
Interventional Study
all
Family Medicine
Recruiting

Everolimus Plus Mycophenolic Acid for Kidney Preservation in Liver Transplant Recipients With Impaired Kidney Function

Liver transplant patients receive potent induction immunosuppression in the form of rabbit anti thymocyte globulin. Investigators believe that in conjunction with this induction regimen, patients can be maintained on Everolimus monotherapy without the risk of rejection.

nephropathy

chronic kidney disease

renal toxicity

renal failure

renal injury

0 views
19 Feb, 2024

Congrats! You have your own personal workspace now.

Learn more

© Copyright TrialX 2025 All rights reserved.